Key Highlights

  • Acumen Pharmaceuticals is trading down 85.77% at $0.33 after its Phase 2 Alzheimer's study missed its primary endpoint.
  • INVO Fertility is trading down 19.36% at $1.73, with no company-specific announcement identified.
  • Azora Therapeutics is trading down 15.57% at $4.12, its second session under the new AZR ticker.
  • Lakewood-Amedex Biotherapeutics is trading down 14.58% at $0.2027 ahead of Phase 2a data expected in the first quarter of 2027.
  • CDT Equity is trading down 14.16% at $0.0661 following a 1-for-25 reverse split approval and convertible note financing.

Which Healthcare Penny Stocks Are Moving the Most Today?

Five healthcare names are trading lower on Oct 30, 2026, and one of them has an unmistakable company-reported catalyst. Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) is trading down 14.58% at $0.2027, and CDT Equity (NASDAQ:CDT) is trading down 14.16% at $0.0661. Acumen Pharmaceuticals (NASDAQ:ABOS) is trading down 85.77% at $0.33, Azora Therapeutics (NASDAQ:AZR) is down 15.57% at $4.12, and INVO Fertility (NASDAQ:IVF) is down 19.36% at $1.73.

All five percentages are measured against the previous close, so they share the same basis, but the share prices sit far apart. Four of the five trade below $2, while AZR at $4.12 is the highest priced of the group.

Only ABOS pairs its drop with a clear announcement, topline Phase 2 results for its Alzheimer's candidate. For LABT, CDT and IVF, no company-specific announcement was identified for the move. For AZR, no separate announcement was identified either, although the company recently changed its name and ticker. The sections below stay with what each company has actually disclosed and flag where figures are stale or unverified.

Lakewood-Amedex Biotherapeutics: why is the stock sliding without an announcement?

Lakewood-Amedex Biotherapeutics is trading down 14.58% at $0.2027, and no company-specific announcement was identified for today's decline. The most recent news found was an Oct 21 release about a poster presented at the IDWeek 2026 conference in Washington, which described laboratory data on its Nu-3 antimicrobial gel.

Those results came from in vitro testing, not patients. The company is a clinical-stage developer, and Nu-3 is aimed at mildly infected diabetic foot ulcers. A Phase 2a study is ongoing, with topline data expected in the first quarter of 2027. The shares reached Nasdaq through a direct listing in April 2026, so the trading history is short, and third-party data lists about 18.68 million shares outstanding.

CDT Equity: what is behind the slide at $0.0661?

CDT Equity is trading down 14.16% at $0.0661, and no company-specific announcement explaining the move was identified. Headlines from Oct 27, an evaluation deal with Manoira, and from Oct 30, about interim U.S. policy on compounded peptide access, were not found to address the decline.

The funding backdrop is heavy. The board approved a 1-for-25 Reverse Stock Split on Sept 25, aimed at maintaining Nasdaq bid-price compliance, and the company issued a $6.75 million senior secured convertible note on Oct 13 after a $2.13 million note in September. Treat the Balance Sheet data with care: a market Capitalization near $205,000 and about 1.12 million shares come from an Oct 19 snapshot, and stockholders' equity of roughly $103 million as of June 30 could not be reconciled with that market value.

Acumen Pharmaceuticals: how bad is the Alzheimer's trial miss for ABOS?

Acumen Pharmaceuticals is trading down 85.77% at $0.33 after topline results from its Phase 2 ALTITUDE-AD study of sabirnetug in early Alzheimer's disease. The trial, which enrolled 542 participants, missed its primary endpoint, the change in the iADRS score at 18 months, at both the 35 mg/kg and 50 mg/kg doses. Key secondary endpoints, including the CDR-SB measure, also failed to reach statistical significance.

The company said it will stop developing sabirnetug and evaluate strategic options, including its Enhanced Brain Delivery program, and will put cash conservation measures in place. Cash and marketable securities were $110.2 million at June 30, 2026, which the company said supported operations into early 2027. Based on about 72.3 million shares outstanding at June 30, the Market Value at $0.33 is roughly $24 million, a calculated figure that sits well below that cash balance.

Azora Therapeutics: what changed after the Adial rebrand?

Azora Therapeutics is trading down 15.57% at $4.12 in its second session under the AZR ticker. The company, formerly Adial Pharmaceuticals, announced the name change on Oct 28, 2026, and the same release said stockholders approved converting the Series A preferred stock from the June Acquisition into common shares. No separate announcement tied to today's decline was identified.

Its lead program, AT177, is an oral, colon-targeted agonist for ulcerative colitis that is still in studies enabling an investigational new drug application, with a Phase 1 trial expected in the first half of 2027. Cash was $28.7 million at June 30, 2026, and management says current cash should fund operations into 2028. The share count of about 2.63 million dates to Aug 12 and predates the preferred conversion, so it is likely outdated.

INVO Fertility: why is IVF down 19.36% with no news?

INVO Fertility is trading down 19.36% at $1.73, and no company-specific announcement was identified. The company operates four fertility clinics in the United States and sells its INVOcell device to outside clinics. Second-quarter Revenue rose 17% to $2.18 million, and Net Income was $888,740, helped by a gain of about $2.5 million tied to the Birmingham acquisition.

The underlying picture is thinner. Adjusted EBITDA was a loss of $1.03 million, and cash was about $3.7 million on June 30. Using the 2,506,969 shares reported as of Aug 14, today's price implies a market value near $4.3 million, a calculated figure that may be stale given a securities offering registration filed in July. One data page showed a price of $0.5782 on Oct 27, which does not reconcile with today's level and could not be verified.

Biotech Penny Names Compared: Average, Spread and Price Gap

The five stocks fell by an average of 29.89% (calculated). That figure is dominated by ABOS; excluding it, the average drop across the other four is 15.92% (calculated), and those four sit in a narrow band between 14.16% and 19.36%.

The spread between the largest and smallest decline, ABOS at 85.77% and CDT at 14.16%, is 71.61 percentage points (calculated). The price gap is also wide: AZR at $4.12 trades at about 62.3 times the price of CDT at $0.0661 (calculated). Only ABOS and, to a lesser degree, AZR have a named corporate event behind the story, and in the other three the move has no identified trigger. All percentages share one basis, the previous close, but the market values quoted for CDT and IVF rest on older share counts.

What to Watch Next: Phase 2a Data, Biomarker Updates and Note Payments

The only fixed date among the five is the Lakewood-Amedex Nu-3 Phase 2a topline readout, expected in the first quarter of 2027. Azora expects to begin its Phase 1 ulcerative colitis trial in the first half of 2027. Acumen has said additional fluid biomarker and imaging data are due in the coming weeks, with no date given.

For CDT, the filing headlines tie a convertible note maturing March 24, 2027 to 24 weekly installments of $168,750, and weekly payments are the item to follow, although that schedule does not tie neatly to the $6.75 million note size and may refer to a different note. No dated release was identified for INVO Fertility's next quarterly report. Financing news remains the common thread across these small-cap names.